Ozkan, M. Et Al. 2005. Inhibition of angiogenesis: Thalidomide or low-molecular-weight heparin?. JOURNAL OF CLINICAL ONCOLOGY , vol.23, no.9 , 2113.

Ozkan, M., Eser, B., ER, O., DOGU, G., & ALTINBAS, M., (2005). Inhibition of angiogenesis: Thalidomide or low-molecular-weight heparin?. JOURNAL OF CLINICAL ONCOLOGY , vol.23, no.9, 2113.

Ozkan, METİN Et Al. "Inhibition of angiogenesis: Thalidomide or low-molecular-weight heparin?," JOURNAL OF CLINICAL ONCOLOGY , vol.23, no.9, 2113, 2005

Ozkan, METİN Et Al. "Inhibition of angiogenesis: Thalidomide or low-molecular-weight heparin?." JOURNAL OF CLINICAL ONCOLOGY , vol.23, no.9, pp.2113, 2005

Ozkan, M. Et Al. (2005) . "Inhibition of angiogenesis: Thalidomide or low-molecular-weight heparin?." JOURNAL OF CLINICAL ONCOLOGY , vol.23, no.9, p.2113.

@article{article, author={METİN ÖZKAN Et Al. }, title={Inhibition of angiogenesis: Thalidomide or low-molecular-weight heparin?}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2005, pages={2113} }